Mr Chris Blick is a Consultant Urological and Robotic Surgeon who has a subspeciality interest in benign prostate conditions and urological cancers.

Mr Blick is a key opinion leader in novel surgical technologies and in the treatment of benign prostatic enlargement offering Aquablation, Rezum, iTind and Echolaser as well as TURP. He is one of the UK’s highest volume aquablation surgeons and has presented his outcome data internationally.

Mr Blick has extensive experience in the management of inflammatory conditions and infections affecting the urinary tract and prostate (prostatitis), and was involved in landmark trials demonstrating the efficacy of the uromune vaccine in recurrent urinary tract infections.

He has over 10 years’ experience in robotic surgery using the DaVinci robot to carry out, nephrectomy (kidney removal). partial nephrectomy, pyeloplasty, partial Cystectomy and ureteric re-implantation.

Mr Chris Blick also has a particular interest in clinical trials. He was successful in becoming the first urological trainee member of the National Institute of Heath Research (NIHR) clinical studies group (CSG). He has been a member of the national renal and bladder cancer CSG, the screening and early prevention (SPED) group and the UK cancer screening and early prevention group of the NIHR.

He is the Research and Development Lead in Urology at the Royal Berkshire Hospital. He has recently received funding and was Chief Investigator in the TARGET trial using augmented reality and artificial intelligence in the diagnosis of prostate cancer. He runs a PhD programme evaluating the role of remote monitoring, machine learning and AI in Urological conditions.

He is also UK Chief Investigator for the EASE Trial examining the role of active surveillance in renal cancer and principle investigator for a number of clinical trials involving bladder, renal and prostate cancer.